STAT3 and head and neck squamous cell carcinoma: According to the study conducted by Sun et al., targeting the STAT3/HOTAIR/EZH2 axis could present a novel therapeutic approach for effectively treating PI3K-activated HNSCC patients with a combination of cisplatin and cetuximab [79].